Abstract
Staging fibrosis is crucial for the prognosis and to determine the rapid need of treatment in patients with chronic hepatitis B (CHB) and C (CHC). The expression of 13 fibrosis-related microRNAs (miRNAs) (miR-20a, miR-21, miR-27a, miR-27b, miR-29a, miR-29c, miR-92a, miR-122, miR-146a, miR-155, miR-221, miR-222, and miR-224) was analyzed in 194 serums and 177 liver biopsies of patients with either CHB or CHC to develop models to diagnose advanced fibrosis and cirrhosis (Metavir F3-F4). In CHB patients, the model (serum miR-122, serum miR-222, platelet count and alkaline phosphatase) was more accurate than APRI and FIB-4 to discriminate in between mild and moderate fibrosis (F1-F2) and F3-F4 (AUC of CHB model: 0.85 vs APRI: 0.70 and FIB-4: 0.81). In CHC patients, the model (hepatic miR-122, hepatic miR-224, platelet count, albumin and alanine aminotransferase) was more accurate than both APRI and FIB-4 to discriminate in between patients with F3-F4 and F1-F2 (AUC of the CHC model = 0.93 vs APRI: 0.86 and FIB-4: 0.79). Most of the miRNAs tested were differentially expressed in patients with CHB and CHC. In particular, serum miR-122 was 28-fold higher in patients with CHB than in those with CHC. Both CHB and CHC models may help for the diagnosis of advanced fibrosis and cirrhosis (F3-F4).
Highlights
IntroductionDifferent sets of miRNAs have been associated with Chronic hepatitis B (CHB) and CHC-induced fibrosis and inflammatory liver diseases[17,18]
The major novelty of our work consists in the identification of two models based on the expression of miRNAs designed to diagnose advanced fibrosis and cirrhosis (F3-F4) in patients with Chronic hepatitis B (CHB) and CHC
We report differential profiles of expression of miRNAs in the liver and serum of patients with CHB and CHC
Summary
Different sets of miRNAs have been associated with CHB and CHC-induced fibrosis and inflammatory liver diseases[17,18]. We previously reported a reduction of the hepatic expression of miR-122 in patients with CHC at the most advanced stages of fibrosis[20]. The main objective of the study was to identify miRNAs associated with fibrosis in order to establish miRNAs-based models to discriminate between patients with advanced fibrosis and cirrhosis (F3-F4) and those with mild to moderate fibrosis (F1-F2) in CHB and CHC. Secondary objectives of this work were to study the correlation between the expression of miRNAs in serum and liver
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
